Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with pemetrexed and platinum-based chemotherapy within its marketing authorisation for previously treated EGFR-positive non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 3873

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
15 February 2021 - 15 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 April 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance